UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction | (Commission | (I.R.S. Employer | ||
| of incorporation) | File Number) | Identification No.) |
(Address of principal executive offices)
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered | ||
| OTCPK |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01. Entry into a Material Definitive Agreement.
Amendment to Development and Supply Agreement
On May 3, 2025, Evofem Biosciences, Inc. (the “Company”) entered into the First Amendment to Development and Supply Agreement (the “Amendment”) on behalf of itself and its wholly owned subsidiaries Evofem Biosciences Operations, Inc. and Evofem, Inc. (“Licensor”), and Pharma 1 Drug Store L.L.C., a United Arab Emirates limited liability company (“Licensee”). The Amendment amends the terms of the Development and Supply Agreement by and between the Company Licensee dated July 17, 2024 (the “License Agreement”), as previously disclosed on the Current Report on Form 8-K filed by the Company on July 23, 2024.
Under the License Agreement, Licensor agreed to sell to Licensee, Licensed Product in package quantities of 12 applicators. Under the terms of the Amendment, the parties wish to add an additional 3-applicator package size of the Licensed Product to be sold by Licensor on the terms and conditions contained in the Amendment.
Item 1.01 of this Current Report on Form 8-K contains only a brief description of the material terms of the Amendment and does not purport to be a complete description of such. Such description is qualified in its entirety by reference to the full text of the Amendment which is attached as Exhibit 10.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 10.1* | First Amendment to Development and Supply Agreement dated May 3, 2025 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
* Furnished herewith.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| EVOFEM BIOSCIENCES, INC. | ||
| Dated: May 8, 2025 | By: | /s/ Saundra Pelletier |
| Saundra Pelletier | ||
| Chief Executive Officer | ||
Exhibit 10.1
CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY “[*]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL.
FIRST AMENDMENT TO DEVELOPMENT AND SUPPLY AGREEMENT
This First Amendment to the Development and Supply Agreement (this “Amendment”) is entered into as of May 3, 2025 (the “Amendment Effective Date”) by and among Evofem Biosciences, Inc., a Delaware corporation (the “Licensor”), and Pharma 1 Drug Store L.L.C., a United Arab Emirates limited liability company (the “Licensee”).
RECITALS
WHEREAS, Licensor and Licensee are parties to that certain Development and supply Agreement, dated as of July 17, 2024 (the “Original Agreement”), pursuant to which Licensor grants Licensee an exclusive license to develop, market, advertise, promote, distribute, offer for sale, sell and import Licensor’s Licensed Product in the Territory;
WHEREAS, the Original Agreement set out terms pursuant to which the Licensor sells to Licensee the Licensed Product in package quantities of 12 applicators of the Licensed Product per package (the “12-Pack”);
WHEREAS, the Parties wish to amend the Original Agreement to add an additional 3- applicator package size of the Licensed Product (the “3-Pack”) to be sold by Licensor to Licensee in accordance with the terms set forth herein;
NOW, THEREFORE, for valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto hereby agree as follows:
AGREEMENT
| 1. | Schedule 2 of the Original Agreement is hereby deleted and replaced with Schedule 2 attached hereto to add the Purchase Price for the 3-Pack of the Licensed Product to be sold by Licensor to Licensee. |
| 2. | Schedule 3 of the Original Agreement is hereby deleted and replaced with Schedule 3 attached hereto to add the Order Terms for the 3-Pack and combinations of 3-Pack and 12- Pack of the Licensed Product to be sold by Licensor to Licensee |
| 3. | Except as explicitly amended or added through this Amendment, all terms, conditions and provisions of the Original Agreement shall remain in full force and effect. |
| 4. | Any capitalized term used herein but not defined herein shall have the meaning ascribed to them in the Original Agreement. |
| 5. | The Original Agreement and this Amendment (including the attachments hereto) shall be read and construed together as a single agreement and the term “Agreement” used in the Original Agreement shall henceforth be deemed a reference to the Original Agreement as amended by this Amendment. |
| 6. | If there is any conflict between the provisions of this Amendment and the Original Agreement, the provisions of this Amendment govern. |
| 7. | This Amendment may be signed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall constitute one and the same instrument |
| -1- |
IN WITNESS WHEREOF, the Parties hereto have duly executed this First Amendment to Development and Supply Agreement as of the Amendment Effective Date.
| Licensor | ||
| Evofem Biosciences, Inc. | ||
| By: | /s/Saundra Pelletier | |
| Print Name: Saundra Pelletier | ||
| Title: | Chief Executive Officer | |
| Date: | 5/2/2025 | |
| Licensee | ||
| Pharma 1 Drug Store L.L.C. | ||
| By: | /s/AbdulWahab Atfah | |
| Print Name: AbdulWahab Atfah | ||
| Title: | Chief Executive Officer | |
| Date: | 5/3/2025 | |
| -2- |
SCHEDULE 2
Pricing
12-Pack Pricing:
Licensor shall charge Licensee a price per 12-Pack (12 applicators) of Licensed Product equal to (a) [*] of Licensor’s Cost of Manufacture on the date of any Order or (b) Cost of Manufacture plus [*] per 12-Pack, whichever is greater on the date any order is placed with a Third Party who manufactures Licensed Products on behalf of Licensor and intended for sales in the Territory.
For the purposes of this Agreement, “Cost of Manufacture” means all amounts paid by Licensor in connection with the production and provision of the Licensed Product to Licensee including, but not limited to, manufacturer costs and fees, shipping, customs, logistics, and all other amounts charged by each Third Party contractor in connection with the manufacturing and delivery of the Licensed Product.
3-Pack Pricing:
Licensor shall charge Licensee a price of [*] per 3-Pack (3 applicators) of Licensed Product. The pricing for the 3-Pack of Licensed Product shall be firm from the Amendment Effective Date through December 31, 2025 for full batches of 3-Packs of the Licensed product. Thereafter, Licensor may increase the price of the 3-Pack on an annual basis to account for any increases in the Cost of Manufacture and such updated pricing will go into effect upon thirty (30) days written notice from Licensor to Licensee, email being sufficient.
Mixed-size Batch Packaging:
If Licensee orders any batch to be split between 3-Packs and 12-Packs, at any Licensor-approved ratio, Licensee agrees to cover any increase in cost or additional charges that are charged by Licensor’s packaging vendor.
| -3- |
SCHEDULE 3
Order Terms
Licensee must order Licensed Products in increments equal to the size of batches then manufactured by or on behalf of Licensor. From time to time, Licensor shall inform Licensee of the required lead time for orders but Licensee acknowledges that this will be no less than six (6) months for both the 12-Pack and 3-Pack of the Licensed Product.
A batch of Licensed Product is, on the Amendment Effective Date, ninety-six thousand (96,000) applicators of Licensed Product. A batch can be packaged entirely into 12-Packs or 3-Packs of Licensed Product. Licensee may request in writing of Licensor (which is subject to the approval of Licensor) to have the Licensed Product packaged in any combination of 3-Packs and 12-Packs of the Licensed Product that constitutes a full batch. Representative ratios per batch of Licensed Product that will be considered by Licensor include:
| Quantity in Order (Per Batch) | Total Applicators of Licensed Product | |||||||||
| 12-Packs | 3-Packs | (Per Batch) | ||||||||
| *8,000 | 0 | 96,000 | ||||||||
| 7,000 | 4,000 | 96,000 | ||||||||
| 6,000 | 8,000 | 96,000 | ||||||||
| 5,000 | 12,000 | 96,000 | ||||||||
| 4,000 | 16,000 | 96,000 | ||||||||
| 3,000 | 20,000 | 96,000 | ||||||||
| 2,500 | 22,000 | 96,000 | ||||||||
| 2,000 | 24,000 | 96,000 | ||||||||
| 1,000 | 28,000 | 96,000 | ||||||||
| 0 | *32,000 | 96,000 | ||||||||
Any packaging ratio other that the two starred above, where the full batch is packaged into one size, either 3-Pack or 12-Pack, may be subject to additional or increased charges as noted in Schedule 2 above. Any and all such additional or increased charges will be paid in full by Licensee in accordance with the terms of this Agreement.
| -4- |